AG-024104
AG-024104 is a CDK inhibitor with Ki values of 2.3 nM (CDK1/cyclinB), 1.8 nM (CDK2/cyclinA), and 0.67 nM (CDK4/cyclinD). AG-024104 functionally inhibits kinase activity of CDK1/cyclinB, CDK2/cyclinA, and CDK4/cyclinD. AG-024104 serves as a negative control for peripheral leukocyte toxicity studies in preclinical development.
For research use only. We do not sell to patients.
- CAS No.: 750575-23-6
- Formula: C24H28F2N6O4S2
- Molecular Weight:566.64
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
AG-024104 potently inhibits purified CDK1/cyclinB, CDK2/cyclinA, and CDK4/cyclinD enzymes with Ki values of 2.3 nM, 1.8 nM, and 0.67 nM, respectively[1].
AG-024104 (4 days) inhibits HCT-116 colorectal carcinoma cell growth with an IC50 of 51 nM[1].
AG-024104 (24 h) induces cytotoxicity in human PBMCs and monkey PBLs with TC50 values of 7.2 μM and 4.0 μM, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HCT-116 colorectal carcinoma cells
-
Concentration:concentrations to achieve 50% growth inhibition (IC50 determination)
-
Incubation Time:4 days
-
Result:Inhibited HCT-116 cell growth with an IC50 of 51 nM.
Parmacokinetics
| Species | Dose | Route | AUC0-24 | T1/2 |
|---|---|---|---|---|
| Rat[1] | 10 mg/kg | i.v. | 2.7 μg·h/mL | 1.4 h |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague Dawley (male, ~10 weeks old)[1]
-
Dosage:10 mg/kg
-
Administration:i.v.; single bolus injection over 2-3 min
-
Result:Remained at ~93% of pre-treatment levels 24 hours post-dose.
Chemical Information
-
CAS No. 750575-23-6
-
Molecular Weight 566.64
-
Formula C24H28F2N6O4S2
-
SMILES
O=C(C=1SC(=NC1N)NC2CCN(CC2)S(=O)(=O)C3=CN=C(OCCN(C)C)C=C3)C=4C(F)=CC=CC4F
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)